Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study.

@article{Rodrguez2006OralRA,
  title={Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study.},
  author={Alfredo E. Rodr{\'i}guez and Juan F Granada and M{\'a}ximo Rodriguez-Alemparte and Cesar Federico Vigo and Juan Rodr{\'i}guez Delgado and Carlos Fern{\'a}ndez-Pereira and Antonio Pocovi and Alfredo Mat{\'i}as Rodr{\'i}guez-Granillo and Daryl Schulz and Albert E. Raizner and I. Gartzia Palacios and William O'neill and Grzegorz L Kaluza and Gregg Whitney Stone},
  journal={Journal of the American College of Cardiology},
  year={2006},
  volume={47 8},
  pages={1522-9}
}
OBJECTIVES The purpose of this study was to assess the role of oral rapamycin in decreased restenosis after bare metal stent implantation. BACKGROUND Small observational studies suggest that the administration of oral rapamycin reduces angiographic restenosis after bare metal stent implantation. METHODS Between September 2003 and September 2004, 100 patients were randomized to either oral rapamycin (6-mg loading dose given 2.7 h before intervention followed by 3 mg/day for 14 days) plus… CONTINUE READING